Tavokinogene telseplasmid is a Gene Therapy owned by OncoSec Medical, and is involved in 11 clinical trials, of which 6 were completed, 4 are ongoing, and 1 is planned.

Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) acts as interleukin-12 (IL-12) alpha and beta activator. Interleukin-12 binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and inhibits tumor angiogenesis. The Oncology Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. The anti-tumor effectiveness of the IL-12 protein is due to the stimulation, proliferation and maturation of both cytotoxic T-cells and NK-cells and the production of IFN-gamma, which results in destruction and elimination of those cells through conventional immune cell processes.

The revenue for Tavokinogene telseplasmid is expected to reach a total of $4.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tavokinogene telseplasmid NPV Report.

Tavokinogene telseplasmid is originated and owned by OncoSec Medical.

Tavokinogene telseplasmid Overview

Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is under development for the treatment of metastatic melanoma and solid tumor. The drug candidate is administered through intratumoral route. The drug candidate is being developed OMS electroImmunotherapy technology that allows delivery of a DNA (nucleic acid) based cytokine coded for interleukin-12, or DNA IL-12. The therapeutic candidate targets cell-surface receptor interleukin-12. It was also under development for the treatment of solid tumors, squamous merkel cell carcinoma, mycosis fungoides, metastatic cerival cancer, cutaneous T-cell lymphoma, head and neck cancer squamous cell carcinoma and triple negative breast cancer.

OncoSec Medical Overview

OncoSec Medical (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company is also identifying and developing novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US

The operating loss of the company was US$37 million in FY2022, compared to an operating loss of US$47.4 million in FY2021. The net loss of the company was US$34.2 million in FY2022, compared to a net loss of US$45.2 million in FY2021.

Quick View – Tavokinogene telseplasmid

Report Segments
  • Innovator
Drug Name
  • Tavokinogene telseplasmid
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.